HUB tumor organoids for oncology drug development
Despite robust indications of activity in existing preclinical models, such as cell lines and animal models, around 95% of new anticancer drugs fail to reach patients. The high attrition rate in cancer drug development has been attributed to poor translatability of preclinical models. Therefore, it has become clear that advanced preclinical models – directly derived from patient tissue and easily expandable in the lab – are needed to improve drug discovery and development.
This fact sheet explores how patient-derived organoids can capture the complexity of cancer and predict patient response to treatment in the clinic.
This content was provided by HUB Organoids.
Submit Your Research to the F1000Research Oncology Gateway
Share your oncology research with the global scientific community through the F1000Research Oncology Gateway. With trusted publishing, open access, and transparent peer review, your work will uphold the highest standards of research integrity while driving innovation in cancer treatment and understanding.
Join a trusted platform that accelerates progress in oncology. Submit your research today at F1000Research Oncology Gateway.
